Jove
Visualize
Contact Us

Related Experiment Videos

Cyclodextrins in oligonucleotide delivery.

E Redenti1, C Pietra, A Gerloczy

  • 1R&D Department, Chiesi Farmaceutici S.p.A., Via Palermo 26/A, 43100 Parma, Italy. e.redenti@chiesigroup.com

Advanced Drug Delivery Reviews
|December 4, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Site and mechanism of the colokinetic action of the ghrelin receptor agonist, HM01.

Neurogastroenterology and motility·2015
Same author

Cyclodextrins in Food Technology and Human Nutrition: Benefits and Limitations.

Critical reviews in food science and nutrition·2015
Same author

New ghrelin agonist, HM01 alleviates constipation and L-dopa-delayed gastric emptying in 6-hydroxydopamine rat model of Parkinson's disease.

Neurogastroenterology and motility·2014
Same author

Efficacy and safety of repeated dosing of netupitant, a neurokinin-1 receptor antagonist, in treating overactive bladder.

Neurourology and urodynamics·2013
Same author

Effect of ghrelin and anamorelin (ONO-7643), a selective ghrelin receptor agonist, on tumor growth in a lung cancer mouse xenograft model.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2013
Same author

Evaluation of the cytotoxicity of beta-cyclodextrin derivatives: evidence for the role of cholesterol extraction.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences·2010
Same journal

Silicone oil in protein drug products and its implications for formulation stability.

Advanced drug delivery reviews·2026
Same journal

Targeted delivery of proteolysis-targeting chimeras (PROTAC) and molecular glue degraders (MGD).

Advanced drug delivery reviews·2026
Same journal

Lysosome-targeting degrader delivery system: from formulation design to biomedical applications.

Advanced drug delivery reviews·2026
Same journal

Anti-PEG antibodies in nanomedicine: Mechanisms, risks, and opportunities.

Advanced drug delivery reviews·2026
Same journal

Optimizing macrophage-targeted intracellular delivery systems for safe and effective immunotherapies.

Advanced drug delivery reviews·2026
Same journal

Light-controlled CRISPR-dCas9 epigenome editing: advanced drug-delivery strategies and oncology applications.

Advanced drug delivery reviews·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Cyclodextrins show promise as carriers for oligonucleotide therapies, enhancing cellular uptake. Specific derivatives may overcome formulation challenges for antisense and decoy oligonucleotides.

Area of Science:

  • Pharmaceutical Science
  • Biotechnology
  • Drug Delivery

Background:

  • Oligonucleotide therapeutics offer targeted gene silencing but face delivery challenges.
  • Existing pharmaceutical excipients struggle with formulating "naked" oligonucleotides.
  • Cellular uptake is a critical barrier for oligonucleotide agent efficacy.

Purpose of the Study:

  • To review recent findings on cyclodextrins as carriers for oligonucleotide agents.
  • To explore the potential of cyclodextrin derivatives in oligonucleotide delivery.
  • To highlight the advantages of cyclodextrins for improving cellular uptake.

Main Methods:

  • Literature review of recent studies on cyclodextrins and oligonucleotide delivery.
  • Analysis of cyclodextrin properties relevant to drug formulation.

Related Experiment Videos

  • Evaluation of cellular interaction mechanisms of cyclodextrins.

    • Main Results:

    • Cyclodextrins possess unique properties enabling interaction with cellular membranes.
    • Certain cyclodextrin derivatives demonstrate potential for enhanced cellular uptake of oligonucleotides.
    • Specific derivatives show promise as excipients for challenging oligonucleotide formulations.

    Conclusions:

    • Cyclodextrins and their derivatives are promising carriers for oligonucleotide agents.
    • Their ability to interact with cell membranes can improve oligonucleotide cellular uptake.
    • These compounds offer a potential solution for formulating "naked" antisense and decoy oligonucleotides.